## **Core Concept**
Idiopathic central precocious puberty (ICPP) is a condition where children exhibit early signs of puberty before the age of 8 in girls and 9 in boys, due to premature activation of the hypothalamic-pituitary-gonadal (HPG) axis. The treatment aims to halt or reverse the advancement of sexual maturation and growth until a more appropriate age. **GnRH agonists** are the mainstay of treatment for ICPP.

## **Why the Correct Answer is Right**
The correct answer, **Triptorelin**, is a **GnRH agonist**. GnRH agonists work by initially stimulating and then downregulating GnRH receptors in the pituitary gland, leading to a decrease in the secretion of gonadotropins (LH and FSH), which in turn reduces the production of sex steroids (estrogen and testosterone) to prepubertal levels. This effectively halts the progression of puberty. Triptorelin is a synthetic decapeptide and a potent GnRH agonist used for the treatment of ICPP, among other conditions.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is blank and does not provide a medication.
- **Option B:** This option is also blank and does not provide a medication.
- **Option D:** This option is blank as well and does not provide a medication.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that the treatment of ICPP with GnRH agonists is generally considered safe and effective but requires monitoring to avoid potential side effects and to assess the adequacy of suppression of the HPG axis. Regular follow-up is crucial to adjust dosing and to monitor for any signs of breakthrough puberty.

## **Correct Answer:** . **Triptorelin**